THE DEAL, AT A GLANCE
2/4 reviewedMithrl
Mithrl
Mithrl combines experimental data with knowledge graphs to identify statistically validated drug target candidates.
Mithrl raised $20M Series A, announced 2026-09-1501What it doesMithrl combines experimental data with knowledge graphs to identify statistically validated drug target candidates.Source-grounded · automated review · Explore ↗
Checked 2026-10-07 · Review due 2026-10-14
Read supporting source ↗Discover novel drug target candidates…
02What happenedMithrl raised $20M Series A, announced 2026-09-15From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗03Why it mattersIts service helps drug researchers find biologically grounded target candidates from their experimental data.Interpretation · Explore ↗
Checked 2026-10-07 · Review due 2026-10-14
Read supporting source ↗Discover novel drug target candidates…
Click a part to explore its evidence. The image is supplied by the cited source.Original record source ↗
Mithrl · Financing Record
Explore source-linked visual explanations for Mithrl. Unsupported claims are withheld while source review continues.
Record 12348 · Recorded date: 2026-09-15
Explore company records →